Advanced search
Publication Cover
Expert Opinion on Therapeutic Targets Volume 7, 2003 - Issue 6
Submit an article Journal homepage
493
Views
60
CrossRef citations to date
0
Altmetric
Review

The therapeutic potential of neuronal KCNQ channel modulators

Valentin K Gribkoff Neuroscience Drug Discovery, Department 401, Bristol-Myers Squibb Pharmaceutical Research Institute, 5 Research Parkway, Wallingford, CT 06492, USA
Pages 737-748 | Published online: 02 Mar 2005

Bibliography

  • COOPER EC, JAN LY: M-channels: neurological diseases, neuromodulation, and drug development. Arch. Neurol (2003) 60:496–500.
  • ••A recent review highlighting the importanceof M-channels in neuronal regulation and their potential as drug targets.
  • JENTSCH TJ: Neuronal KCNQ potassium channels: physiology and role in disease. Nat. Rev Neurosci. (2000) 1:21–30.
  • ROBBINS J: KCNQ potassium channels: physiology, pathophysiology, and pharmacology. Pharmacol Ther. (2001) 90:1–19.
  • BIEVERT C, SCHROEDER BC, KUBISCH C et al.: A potassium channel mutation in neonatal human epilepsy. Science (1998) 279:403–406.
  • CHARLIER C, SINGH NA, RYAN SG et al: A pore mutation in a novel KQT-like potassium channel gene in an idiopathic epilepsy family. Nat. Genet. (1998) 18:53–55.
  • SINGH NA, CHARLIER C, STAUFFER D et al: A novel potassium channel gene, KCNQ2, is mutated in an inherited epilepsy of newborns. Nat. Genet. (1998) 18:25–29.
  • PICARD S, LACROIX P: QT interval prolongation and cardiac risk assessment for novel drugs. Curr. Opin. Invest. Drugs (2003) 4:303–308.
  • GRIBKOFF VK, STARRETT JE: An assessment of the present and future roles of non-ligand gated ion channel modulators as CNS therapeutics. Expert Opin. Pharmacother. (1999) 1:61–70.
  • WICKENDEN AD: Potassium channels as anti-epileptic drug targets. Neuropharmacology (2002) 43:1055–1060.
  • ••A good review of the potential ofKCNQ modulation in hyperexcitability disorders.
  • FORD JW, STEVENS EB, TREHERNE JM et al: Potassium channels: gene family, therapeutic relevance, high-throughput screening technologies and drug discovery. Frog. Drug Res. (2002) 58:133–168.
  • WILLUMSEN NJ, BECH M, OLESEN SP et al.: High throughput electrophysiology: new perspectives for ion channel drug discovery. Receptors Channels (2003) 9:3–12.
  • GRIBKOFF VK, STARRETT JE: Advances in technologies for the discovery and characterization of ion channel modulators: focus on potassium channels. Annu. Rep. Med. Chem. (2002) 37:237–246.
  • ARMSTRONG C: Voltage-gated K channels. Sci. STKE (2003) re10:1–7.
  • BRINGMANN A, FRANCKE M, PANNICKE T et al: Role of glial K+ channels in ontogeny and gliosis: a hypothesis based upon studies on Muller cells. Glia (2000) 29:35–44.
  • JACKSON WF: Ion channels and vascular tone. Hypertension (2000) 35:173–178.
  • MATHIE A, CLARKE CE, RANATUNGA KM, VEALE EL: What are the roles of the many different types of potassium channel expressed in cerebellar granule cells? Cerebellum (2003) 2:11–25.
  • VOGALIS F: Potassium channels in gastrointestinal smooth muscle. Autonom. Pharmacol (2000) 20:207–219.
  • WONDERLIN WE STROBL JS: Potassium channels, proliferation and G1 progression. J. Membr. Biol. (1996) 154:91–107.
  • YELLEN G: The voltage-gated potassium channels and their relatives. Nature (2002) 419:35–42.
  • ••Useful review of voltage-dependentpotassium channels.
  • ARCHER SL: Potassium channels and erectile dysfunction. Vasty] Pharmacol (2002) 38:61–71.
  • GRIBKOFF VK, STARRETT JE, DWORETZKY SI: Maxi-K potassium channels: form, function, and modulation of a class of endogenous regulators of intracellular calcium. Neuroscientist (2001) 7:166–177.
  • SEINO S, MIKI T: Physiological and pathophysiological roles of ATP-sensitive K+ channels. Frog. Biophys. Mol Biol. (2003) 81:133–176.
  • JOHNSON D, CHRISTIE BR, FRICK A et al: Active dendrites, potassium channels and synaptic plasticity. Philos. Trans. R. Soc. Lond. B Biol. Sci. (2003) 358:667–674.
  • JAHANGIR A, SHEN W, TERZIC A: Potassium channel openers: therapeutic potential in cardiology and medicine. Expert Opin. Pharmacother. (2001) 2:1995–2010.
  • GRIBKOFF VK, STARRETT JE, DWORETZKY SI et al.: Targeting acute ischemic stroke with a calcium-sensitive opener of maxi-K potassium channels. Nat. Med. (2001) 7:471–477.
  • SCHRODER RL, JESPERSEN T, CHRISTOPHERSEN P et al: KCNQ4 channel activation by BMS-204352 and retigabine. Neuropharmacology (2001) 40:888–898.
  • DUPUIS DS, SCHRODER RL, JESPERSEN T et al: Activation of KCNQ5 channels stably expressed in HEK293 cells by BMS-204352. Eur. Pharmacol (2002) 437:129–137.
  • GRIBKOFF VK, CHAMPIGNY G, BARBRY P et al: The substituted benzimidazolone N5004 is an opener of the cystic fibrosis chloride channel. J. Biol. Chem. (1994) 269:10983–10986.
  • MCKAY MC, DWORETZKY SI, MEANWELL NA et al.: Opening of large-conductance calcium-activated potassium channels by the substituted benzimidazolone N5004. Neurophysiol (1994) 71: 1873-1882.
  • GRIBKOFF VK, STARRETT JE, DWORETZKY SI: The pharmacology and molecular biology of large-conductance calcium-activated (BK) potassium channels. Adv. Pharmacol (1997) 37:319–348.
  • YUAN A, SANTI CM, WEI A et al: The sodium-activated potassium channel is encoded by a member of the Slo gene family. Neuron (2003) 37:765–773.
  • LIU Y, LIU D, HEATH L et al: Direct activation of an inwardly rectifying potassium channel by arachidonic acid. Mol Pharmacol (2001) 59:1061–1068.
  • LU T, HOSHI T, WEINTRAUB NL, SPECTOR AA, LEE HC: Activation of ATP-sensitive K+ channels by epoxyeicosatrienoic acids in rat cardiac ventricular myocytes. Physiol (2001) 537:811–827.
  • LU M, HEBERT SC, GIEBISCH G: Hydrolyzable ATP and PIP(2) modulate the small conductance K+ channel in apical membranes of rat cortical-collecting duct (CCD). .1 Gen. Physic] (2002) 120:603–615.
  • SCHULZE D, KRAUTER T, FRITZENSCHAFT H, SOOM M, BAUKROWITZ T: Phosphatidylinositol 4,5-bisphosphate (PIP2) modulation of ATP and pH sensitivity in KIR channels. A tale of an active and a silent PIP2 site in the N terminus. 'Bid Chem. (2003) 278:10500–10505.
  • BIENENGRAEBER M, ALEKSEEV AE, ABRAHAM MR et al: ATPase activity of the sulphonylurea receptor: a catalytic function for the KATP channel complex. FASEB J. (2000) 14:1943–1952.
  • YANG WP, LEVESQUE PC, LITTLE WA et al.: Functional expression of two KyLQT1-related potassium channels responsible for an inherited idiopathic epilepsy. Biol Chem. (1998) 273:19419–19423.
  • OKADA M, ZHU G, HIROSE S et al: Age-dependent modulation of hippocampal excitability by KCNQ-channels. Epilepsy Res. (2003) 53:81–94.
  • BIEVERT C, STEINLEIN OK: Structural and mutational analysis of KCNQ2, the major gene locus for benign familial neonatal convulsions. Hum. Genet. (1999) 104:234–240.
  • ••An excellent genetic analysis ofKCNQ mutations leading to BFNCs.
  • DEDEK K, KUNATH B, KANANURA C et al: Myokymia and neonatal epilepsy caused by a mutation in the voltage sensor of the KCNQ2 K+ channel. Proc. Nat] Acad. Sci. USA (2001) 98:12272–12277.
  • SINGH N, WESTENSKOW P, CHARLIER C et al: KCNQ2 and KCNQ3 potassium channel genes in benign familial neonatal convulsions: expansion of the functional and mutation spectrum. Brain (2003) 126:1–12.
  • KUBISCH C, SCHROEDER BC, FRIEDRICH T et al: KCNQ4, a novel potassium channel expressed in sensory outer hair cells, is mutated in dominant deafness. Cell (1999) 96:437–446.
  • KHARKO VETS T, HARDELIN JP, SARIEDDINE S et al: KCNQ4, a K+ channel mutated in a form of dominant deafness, is expressed in the inner ear and central auditory canal. Proc. Natl. Acad. Sci. USA (2000) 97:4333–4338.
  • LERCHE C, SCHERER CR, SEEBOHM G et al: Molecular cloning and functional expression of KCNQ5, a potassium channel subunit that may contribute to neuronal M-channel diversity. ./. Biol. Chem. (2000) 275:22395–22400.
  • SCHROEDER BC, HECHENBERGER M, WEINREICH F, KUBISCH C, JENTSCH TJ: KCNQ5, a novel potassium channel broadly expressed in brain, mediates M-channel currents. J. Biol. Chem. (2000) 275:24089–24095.
  • FRIEDEL HA, FITTON A: Flupirtine. A review of its pharmacological properties, and therapeutic efficacy in pain states. Drugs (1993) 45:548–569.
  • HOVINGA CA: Novel anticonvulsant medications in development. Expert Opin. Invest. Drugs (2002) 11:1387–1406.
  • MAIN MJ, CRYAN JE, DUPERE JR et al:Modulation of KCNQ2/3 potassium channels by the novel anticonvulsant retigabine. Mol Pharmacol (2000) 58:253–262.
  • PASSMORE GM, SELYANKO AA, MISTRY M et al: KCNQ/M currents in sensory neurons: significance for pain therapy../. Neurosci. (2003) 23:7227–7236.
  • ••Basic evidence suggesting KCNQ channelInvolvement in pain pathways.
  • TATULIAN L, DELMAS P, ABOGADIE FC, BROWN DA: Activation of expressed KCNQ potassium currents and native neuronal M-type potassium currents by the anticonvulsant drug retigabine. Neurosci. (2001) 21:5535–5545.
  • TATULIAN L, BROWN DA: Effect of the KCNQ potassium channel opener retigabine on single KCNQ2/3 channels expressed in CHO cells. J. Physic] (2003) 549:57–63.
  • RUNDFELDT C, NETZER R: Investigations into the mechanism of action of the new anticonvulsant retigabine. Interaction with GABAergic and glutamatergic neurotransmission and voltage gated ion channels. Armeimittelforschung (2000) 50:1063–1070.
  • YUS-NAJERA E, MUNOZ A, SALVADOR N et al.: Localization of KCNQ5 in the normal and epileptic human temporal neocortex and hippocampal formation. Neuroscience (2003) 120:353–364.
  • TINEL N, LAURITZEN I, CHOUABE C, LAZDUNSKI M, BORSOTTO M: The KCNQ2 potassium channel: splice variants, functional and developmental expression. Brain localization and comparison with KCNQ3. FEBS Lett. (1998) 438:171–176.
  • PAN Z, SELYANKO AA, HADLEY JK, BROWN DA, DIXON JE, MCKINNON D: Alternative splicing of KCNQ2 potassium channel transcripts contributes to the functional diversity of M-currents. Physiol (2001) 531:347–358.
  • NAKAMURA M, WATANABE H, KUBO Y et al.: KQT2, a new putative potassium channel family produced by alternative splicing. Isolation, genomic structure, and alternative splicing of the putative potassium channels. Receptors Channels (1998) 5:255–271.
  • SMITH JS, IANNOTTI CA, DARGIS P,CHRISTIAN EP, AIYAR J: Differential expression of KCNQ2 splice variants: implications to M current function during development. J. Neurosci. (2001) 15:1096–1103.
  • ADAMS PR, BROWN DA, CONSTANTI A: Pharmacological inhibition of the M-current. Physiol (1982) 332:223–262.
  • WANG HS, PAN Z, SHI W et al.: KCNQ2 and KCNQ3 potassium channel subunits: molecular correlates of the M-channel. Sdence (1998) 282: 1890-1893.
  • ••This is the paper that first identifiedKCNQ channels as the molecular substrate of the M-channel.
  • HADLEY JK, PASSMORE GM, TATULIAN L et al.: Stoichiometry of expressed KCNQ2/KCNQ3 potassium channels and subunit composition of native ganglionic M channels deduced from block by tetraethylammonium. j Neurosci. (2003) 23:5012–5019.
  • SHAH MM, MISTRY M, MARSH SJ, BROWN DA, DELMAS P: Molecular correlates of the M-current in cultured rat hippocampal neurons. Physiol (2002) 544:29–37.
  • SUH BC, HILLE B: Recovery from muscarinic modulation of M current channels requires phosphatidylinositol 4, 5-bisphosphate synthesis. Neuron (2002) 35:507–520.
  • ••This study first demonstrated thatPIP2 hydrolysis is a likely contributor to the suppression of KCNQ/M-channels underlying muscarinic depolarisation.
  • ZHANG H, CRACIUN LC, MIRSHAHI T et al: PIP(2) activates KCNQ channels, and its hydrolysis underlies receptor-mediated inhibition of M currents. Neuron (2003) 37:963–975.
  • ••This paper first demonstrated directactivation of KCNQ channels by PIP2, and that mutations in the C terminus could lead to suppression of PIP2 responsivity.
  • HOSHI N, ZHANG JS, OMAKI M et al: AKAP150 signalling complex promotes suppression of the M-current by muscarinic agonists. Nature Neurosci. (2003) 6:564–571.
  • YUS-NAJERA E, SANTANA-CASTRO I, VILLARROEL A: The identification and characterization of a noncontinuous calmodulin-binding site in noninactivating voltage-dependent KCNQ potassium channels. J. Biol. Chem. (2002) 277:28545–28553.
  • WEN H, LEVITAN TB: Calmodulin is an auxiliary subunit of KCNQ23 potassium channels. J. Neurosci. (2002) 22:7991–8001.
  • GAMPER N, STOCKLAND JD, SHAPIRO MS: Subunit-specific modulation of KCNQ potassium channels by Src tyrosine kinase. Neurosci. (2003) 23:84–95.
  • FINNERUP NB, GOTTRUP H, JENSEN TS: Anticonvulsants in central pain. Expert Opin. Pharmacother. (2002) 3:1411–1420.
  • CORTELLI P, PIERANGELI G: Chronic pain - autonomic interactions. Neurol Sci. (2003) 24:S68–S70.
  • LIDBECK J: Central hyperexcitability in chronic musculoskeletal pain: a conceptual breakthrough with multiple clinical implications. Pain Res. Manag. (2002) 7:81–92.
  • PONGS O: Voltage-gated potassium channels: from hyperexcitability to excitement. FEBS Lett. (1999) 452:31–35.
  • DOST R, RUNDFELDT C: The anticonvulsant retigabine potently suppresses epileptiform discharges in the low Ca ++ and low Mg ++ model in the hippocampal slice preparation. Epilepsy Res. (2000) 38:53–66.
  • ROSTOCK A, TOBER C, RUNDFELDT C et al.: D-23129: a new anticonvulsant with a broad spectrum activity in animal models of epileptic seizures. Epilepsy Res. (1996) 23:211–223.
  • TOBER C, ROSTOCK A, RUNDFELDT C, BARTSCH R: D-23129: a potent anticonvulsant in the amygdala kindling model of complex partial seizures. Eur. Pharmacol. (1996) 303:163–169.
  • WU YJ, BOISSARD CG, GRECO C et al.:(S) -N- [1 (3 morpholin-4-ylpheny11-3-phenylacrylamide: an orally bioavailable KCNQ2 opener with significant activity in a cortical spreading depression model of migraine. I Med. Chem. (2003) 46:197–200.
  • WHEELER G: Gabapentin. Pfizer. Curr. Opin. Invest. Drugs (2002) 3:470–477.
  • BLACKBURN-MUNRO G, JENSEN BS: The anticonvulsant retigabine attenuates nociceptive behaviours in rat models of persistent and neuropathic pain. Eur. Pharmacol (2003) 460:109–116.
  • ••This study first demonstrated thatretigabine, a KCNQ opener, had efficacy in some animal pain models.
  • SHIMAZAWA M, HARA H: An experimental model of migraine with aura: cortical hypoperfusion following spreading depression in the awake and freely moving rat. Clin. Exp. Pharmacol Physiol. (1996) 23:890–892.
  • WELCH KM: Concepts of migraine headache pathogenesis: insights into mechanisms of chronicity and new drug targets. Neurol Li. (2003) 24:S149–S153.
  • BARTSCH T, GOADSBY PJ: The trigeminocervical complex and migraine: current concepts and synthesis. Curl: Pain Headache Rep. (2003) 7:371–376.
  • OLIVER D, KNIPPER M, DERST C, FAKLER B: Resting potential and submembrane calcium concentration of inner hair cells in the isolated mouse cochlea are set by KCNQ-type potassium channels. Neurosci. (2003) 23:2141–2149.
  • NOUVIAN R, RUEL J, WANG J, GUITTON MJ, PUJOL R, PUEL JL: Degeneration of sensory outer hair cells following pharmacological blockade of cochlear KCNQ channels in the adult guinea pig. Eur. Neurosci. (2003) 17:2553–2562.
  • SANGUINETTI MC: Dysfunction of delayed rectifier potassium channels in an inherited cardiac arrhythmia. Ann. NY Arad Sci. (1999) 868:406–413.
  • DEDEK K, WALDEGGER S: Colocalization of KCNQl/KCNE channel subunits in the mouse gastrointestinal tract. PlIugers Arch. Eur. I Pharmacol (2001) 442:896–902.
  • ZACZEK R, CHORVAT RJ, BROWN BS: Linopirdine: pharmacology of a neurotransmitter release enhancer. CNS Drug Rev. (1997) 3:103–119.
  • ZACZEK R, CHORVAT RJ, SAYE JA et al.: Two new potent neurotransmitter release enhancers, 10,10-bis(4-pyrinylmethyl)-0(10H)-anthtacenone and 10,10-bn (2-fluoro-4-pyridinylmethy0-9(10H)-anthracenone: comparison to linopirdine. Pharmacol Exp. Ther. (1998) 285:724–730.
  • SAFER DJ: The central effects of scopolamine in man. Biol. Psychiatry (1971) 3:347–355.
  • GAGE FH, CHEN KS, BUZSAKI G, ARMSTRONG D: Experimental approaches to age-related cognitive impairments. Neurobiol Aging (1988) 9:645–655.
  • EBERT U, KIRCH W: Scopolamine modelof dementia: electroencephalogram findings and cognitive performance. Eur. Clin. Invest. (1998) 28:944–949.
  • SUNDERLAND T, TARIOT PN, WEINGARTNER H et al: Pharmacologic modeling of Alzheimer's disease. Prog. Neuropsychopharmacol (1986) 10:599–610.
  • BARTUS RT, DEAN RL, BEER B, LIPPA AS: The cholinergic hypothesis of geriatric memory dysfunction. Science (1982) 217:408–414.
  • FIBIGER HC: Cholinergic mechanisms in learning, memory and dementia: a review of recent evidence. Trends Neurosci. (1991) 14:220–223.
  • BLOKLAND A: Acetylcholine: a neurotransmitter for learning and memory? Brain Res. Brain Res. Rev (1995) 21:285–300.
  • SUGIMOTO H, YAMANISHI Y, IIMURA Y, KAWAKAMI Y: Donepezil hydrochloride (E2020) and other acetylcholinesterase inhibitors. Curr. Med. Chem. (2000) 7:303–339.
  • ROGAWSI MA, WENK GL: The neuropharmacological basis for the use of memantine in the treatment of Alzheimer's disease. CNS Drug Rev (2003) 9:275–308.
  • BLAND BH: The physiology and pharmacology of hippocampal formation O rhythms. Frog. Neurobiol (1986) 26:1–54.
  • BARNES JC, ROBERTS FF: Central effects of muscarinic agonists and antagonists on hippocampal O rhythm and blood pressure in the anaesthetized rat. Eur. Pharmacol (1991) 195:233–240.
  • KINNEY GG, PATINO P, MERMET-BOUVIER Y, STARRETT JE, GRIBKOFF VK: Cognition-enhancing drugs increase stimulated hippocampal O rhythm amplitude in the urethane-anesthetized rat. J. Pharmacol Exp. Ther. (1999) 291:99–106.
  • DIAMOND DM, DUNWIDDIE TV, ROSE GM: Characteristics of hippocampal primed burst potentiation in vitro and in the awake rat. J. Neurosci. (1988) 8:4079–4088.
  • TOMBAUGH GC, ROWE WB, CHOW AR, MICHAEL TH, ROSE GM: O-Frequency synaptic potentiation in CA1 in vitro distinguishes cognitively impaired from unimpaired aged Fischer 344 rats. Neurosci. (2002) 15:9932–9940.

Website

  • http:Thuphar-db.orghupharddindex.html CATERALL W, GUTMAN G, CHANDY G (Eds): The NC-IUPHAR compendium of voltage-gated ion channels. Patent

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.